Toxicity of high-activity 111in-octreotide therapy in patients with disseminated neuroendocrine tumours

Nuclear Medicine Communications

Volumn 21, Issue 1, 2000, Pages 97-102

  Caplin, M E ^a   Mielcarek, W ^a   Buscombe, J R ^a   Jones, A L ^a   Croasdale, P L ^a   Cooper, M S ^a   Burroughs, A K ^a   Hilson, A J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811;

ADULT; AGED; ARTICLE; BONE; CARCINOID; CLINICAL TRIAL; FEMALE; GASTRINOMA; GLOMERULUS FILTRATION RATE; HUMAN; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; RADIATION EXPOSURE; SCINTISCANNING;

ADULT; AGED; BONE AND BONES; CARCINOID TUMOR; FEMALE; GASTRINOMA; GLOMERULAR FILTRATION RATE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS;

EID: 0033628490     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200001000-00016     Document Type: Review

References (16)

1. Reubi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43: 27-35.
2. Krenning EP, Bakker EP, Breenman WAP et al. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet 1989; i: 242-244.
3. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin imaging with indium-111 pentetreotide in gastroenteropancreatic neuroendocrine tumours: Safety, efficacy and impact on patient management. J Nucl Med 1995; 36: 542-549.
4. 3]-octreotide: The Rotterdam experience of more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
5. 1] octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131: 577-581.
6. Lambert SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostain receptor imaging in the localisation of endocrine tumours. N Eng J Med 1990; 323: 1246-1249.
7. Hoefnagel CA. Metaiodobenzylguanadine and somatostatin in oncology: Role in management of neural crest tumours. Eur J Nucl Med 1994; 21: 561-581.
8. 1]-octreotide: A case history. Ann NY Acad Sci 1994; 733: 496-506.
9. Stabin MG, Kooil PPM, Bakker WH et al. Radiation dosimetry for indium-111 pentetreotide. J Nucl Med 1997; 38: 1919-1922.
10. Anderson P, Forssel-Aranson E, Johanson V et al. Internalization of indium-111 into human neuroendocrine tumour cells after incubation with indium-111 DTPA-D-Phe1-octreotide. J Nucl Med 1996; 37: 2002-2006.
11. Bernard BF, Krenning EP, Breeman WAP et al. D-lysine reduction of Indium-111 Octreotide and Yttrium-90 Octreotide renal uptake. J Nucl Med 1997; 38: 1929-1933.
12. Atiya A, Malik M, Ure S, Shevlin L, Caj D, Branicardi FC. Immunomodulatory activity of somatostatin receptor subtype analogues on human peripheral blood lymphocytes. Transplant Proc 1997; 29: 2151.
13. 111In has detrimental effects on human lymphocytes: Concise communication. J Nucl Med 1983; 24: 1012-1019.
14. de Jong M, Breeman W, Bakker WH et al. Comparison of In-111 labelled somatostatin analogs for tumour scintigraphy and radionuclide therapy. Cancer Res 1998; 58: 437-441.
15. 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Am 1998; 4: 84-102.
16. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrman R, Maecke HR. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998; 351: 417-418.